
BMS-986278, an oral lysophosphatidic acid receptor 1 (LPA) antagonist, demonstrated efficacy and safety in reducing the rate of percent of predicted FVC decline over 26 weeks in patients with progressive fibrotic interstitial lung disease (ILD). Treatment differences were 1.6% (30mg) and 3.2% (60mg) compared to placebo, supporting further development for various forms of progressive fibrotic ILD.
Like
Save
Share